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Abstract
Background: The influence of serum leptin levels on nutritional status and survival in chronic hemodialysis
patients remained to be elucidated. We conducted a prospective longitudinal study of leptin levels and nutritional
parameters to determine whether changes of serum leptin levels modify nutritional status and survival in a cohort
of prevalent hemodialysis patients.
Methods: Leptin, dietary energy and protein intake, biochemical markers of nutrition and body composition
(anthropometry and bioimpedance analysis) were measured at baseline and at 6, 12, 18 and 24 months following
enrollment, in 101 prevalent hemodialysis patients (37% women) with a mean age of 64.6 ± 11.5 years.
Observation of this cohort was continued over 2 additional years. Changes in repeated measures were evaluated,
with adjustment for baseline differences in demographic and clinical parameters.
Results: Significant reduction of leptin levels with time were observed (linear estimate: -2.5010 ± 0.57 ng/ml/2y;
p < 0.001) with a more rapid decline in leptin levels in the highest leptin tertile in both unadjusted (p = 0.007) and
fully adjusted (p = 0.047) models. A significant reduction in body composition parameters over time was observed,
but was not influenced by leptin (leptin-by-time interactions were not significant). No significant associations were
noted between leptin levels and changes in dietary protein or energy intake, or laboratory nutritional markers.
Finally, cumulative incidences of survival were unaffected by the baseline serum leptin levels.
Conclusions: Thus leptin levels reflect fat mass depots, rather than independently contributing to uremic anorexia
or modifying nutritional status and/or survival in chronic hemodialysis patients. The importance of such information
is high if leptin is contemplated as a potential therapeutic target in hemodialysis patients.
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Background
In recent years, the number of patients with end-stage
renal disease (ESRD) has been increasing worldwide [1].
Depending in part upon the method used to evaluate
nutritional status and the population studied, from 40 to
70 percent of patients with ESRD are malnourished [2,3]
resulting in poor clinical outcomes [4]. Among the
mechanisms responsible for malnutrition, leptin was
believed to influence nutritional markers in patients with
ESRD [5]. Leptin is a 16-kDa protein identified as the
product of the obese gene; it is exclusively produced in
adipocytes, and regulates food intake and energy expen-
diture in animal models [6]. Leptin decreases food intake
by decreasing NPY (neuropeptide Y - one of the most
potent stimulators of food intake) mRNA [7] and increas-
ing alpha-MSH (alpha-melanocyte-stimulating hormone
- an inhibitor of food intake) [8]. Besides linking adiposity
and central nervous circuits to reduced appetite and
enhanced energy expenditure in the general population
[9], leptin has been shown to increase overall sympathetic
nerve activity [10], facilitate glucose utilization and
improve insulin sensitivity [11]. Furthermore, the pro-
spective West of Scotland Coronary Prevention Study
(WOSCOPS) reported that elevated leptin increases the
relative risk of cardio-vascular disease in the general
population independently of fat mass [12].
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vated in patients with renal failure, particularly when
compared to age, gender and body mass index (BMI)-
matched controls [13,14]. However, the role of hyperlep-
tinemia in ESRD patients is somewhat unconventional.
In contrast with its anorexogenic effects recognized in
the general population [9] and even in experimental
models of uremia (in subtotal nephrectomized and lep-
tin receptor-deficient [db/db] mice) [15], leptin has not
been reported to affect perceived appetite and nutrient
intake in dialysis patients [16,17]. Although in some
observational studies, increased serum leptin concentra-
tions were observed in ESRD patients in parallel with
loss of lean body mass [18,19] or with hypoalbuminemia
and low protein intake [20], some others failed to find
any correlation between hyperleptinemia and weight
change [9] or lean mass [21] in this population. More-
over, several clinical studies suggested that leptin is a
negative acute phase protein [22] and can serve as a
marker of adequate nutritional status, rather than an
appetite-reducing uremic toxin in hemodialysis patients
[23-25]. Finally, the relationship between elevated serum
leptin levels and clinical outcomes in ESRD has not
been fully defined. In one small prospective cohort of
hemodialysis patients, lower baseline serum leptin levels
predicted mortality [26], but neither changes in leptin
over time were measured, nor were leptin levels normal-
ized to body fat mass in this study.
Thus, the influence of serum leptin levels on nutri-
tional status and survival in chronic hemodialysis
patients remained to be elucidated. In view of leptin’s
physiological role, information on effects of prolonged
hyperleptinemia (independent of fat mass) on nutritional
status of chronic hemodialysis patients, which may also
impact on their survival, would be of interest. The aim
of the present prospective longitudinal study was there-
fore to study longitudinal changes in serum leptin levels
and to relate them to the changes in nutritional markers
and survival in chronic hemodialysis patients.
Methods
Patients
This prospective observational study was approved by the
Ethics Committee of Assaf Harofeh Medical Center (Zer-
ifin, Affiliated to the Sackler Faculty of Medicine Tel
Aviv University, Israel). Informed consent was obtained
before any trial-related activities. Patients were eligible
for entry when they had been on HD therapy for at least
3 months and were 18 years or older, with no clinically
active cardio-vascular or infectious diseases on entry. We
excluded patients with edema, pleural effusion or ascites
at their initial assessment, as well as patients with malig-
nant disease, liver cirrhosis, neuro-muscular diseases,
amputations or any deformities of the body. Exclusion
criteria at the entry of the study also included co-morbid-
ity (auto-immune disease and/or acute infections) and/or
medication (prednisone) that might interfere with plasma
leptin concentrations. A flow chart of the study is pre-
sented in Figure 1. In total, 101 patients (64 men and 37
women) with a mean age of 64.6 ± 11.5 years, receiving
maintenance hemodialysis treatment at our outpatient
HD clinic, were included in the study. Of the patients
studied, 52 were diabetic (all diabetic patients had type 2
diabetes). Study measurements were performed at base-
line and at 6, 12, 18 and 24 months from enrollment.
After the longitudinal measurements ended, we contin-
ued clinical observation on our cohort during 2 addi-
tional years. Thus, in total, the study period extended 35
± 17 months. During this period, 33 patients (32.7%) died
(the main causes of death were cardio-vascular [12 of 33
patients; 36.4%] and sepsis [12 of 33 patients; 36.4%]), 13
patients (12.9%) underwent kidney transplantation, 3
patients (3.0%) changed dialysis modality, and 10 patients
(10.0%) transferred to other hemodialysis units. All
patients underwent regular dialysis via their vascular
access (81.2% of patients had arterio-venous fistula) 4-5 h
three times per week at a blood flow rate of 250-300 ml/
min. Bicarbonate dialysate (30 mEq/L) at a dialysis solu-
tion flow rate of 500 ml/min was used in all cases. All
dialysis was performed with biocompatible dialyzer mem-
b r a n ew i t has u r f a c ea r e ao f1 . 0 - 1 . 8m
2. The efficiency of
the dialysis was assessed based on the delivered dose of
dialysis (Kt/V urea) using a single-pool urea kinetic
model (mean Kt/V was1.31 ± 0.23 in our population).
Information on vascular disease (cerebral vascular,
peripheral vascular and heart disease) was obtained
from a detailed medical history.
Most patients were required antihypertensive medica-
tions as well as other drugs commonly used in ESRD,
such as phosphate and potassium binders, diuretics, and
supplements of vitamins B, C, and D.
Dietary intake
A continuous 3-day dietary history (which included a
dialysis day, a weekend day and a non-dialysis day) was
recorded on a self-completed food diary. Then, dietary
energy and protein intake were calculated and normal-
ized for adjusted body weight (ABW) by the following
formula [27]:
ABW = ([Patient’s actual weight - SBW] × 0.25) + SBW.
SBW - standard body weight was determined by the
National Healthand Nutrition Examination Survey II
(NHANES II) population medians for age, sex, frame
size, and stature [27].
Dietary protein intake was also estimated by the pro-
tein catabolic rate (PCR) calculation from the patient’s
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gle-pool model urea kinetics was used to estimate the
nPCR.
Anthropometric measurements
BMI, triceps skinfold thickness (TSF), mid arm circum-
ference (MAC) and calculated mid arm muscle circum-
ference (MAMC) were measured as anthropometric
variables. The BMI was calculated as dry weight in kilo-
grams divided by the square of height in meters. TSF
was measured with a conventional skinfold caliper using
standard techniques. Mid arm circumference was mea-
sured with a plastic measuring tape. MAMC was esti-
mated as follows:
MAMC (cm) = mid arm circumference (cm) − 0.314 × TSF (mm).
Body composition analysis
Body composition was determined by body impedance
analysis (B.I.A. Nutriguard- M, Data-Input, Frankfurt, Ger-
many). We used gel-based electrodes specifically devel-
oped for BIA measurements - Bianostic AT (Data-Input
GmbH). On the day of blood collection, patients under-
went BIA measurement at approximately 30 minutes post-
dialysis. BIA electrodes were placed on the same body side
used for anthropometric measurements. The multi-fre-
quency technique was used. FFM was calculated by using
the approach of Kyle et al. validated by dual-energy x-ray
absorptiometry on 343 healthy adult subjects [29]:
FFM = − 4.104 + (0.518 × height2/resistance) + (0.231 × weight)
+ (0.130 × reactance) + (4.229 × sex : men = 1,women = 0).
Fat mass and fat free mass were standardized by
squared height (m
2), and expressed in kg/m
2 as fat mass
Figure 1 Flow diagram of the study.
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respectively.
Phase angle (PA) describes the relationship between
the two vector components of impedance [reactance
and resistance] of the human body to an alternating
electric current. PA has been shown to provide a BIA
prognostic index of morbidity and mortality [30].
Laboratory evaluation
Blood samples were taken in a non-fasting state before a
midweek hemodialysis session. CBC, creatinine, urea,
albumin, transferrin and total cholesterol were measured
by routine laboratory methods. IL-6 and leptin were
measured in plasma samples using commercially avail-
able enzyme-linked immunosorbent assay (ELISA) kits
(R&D System, Minneapolis, MN, USA) according to the
manufacturer’s protocol. The mean minimal detectable
level for IL-6 was 0.7 pg/ml, and 7.8 pg/ml for leptin.
Intra-assay and inter-assay coefficients of variation for
IL-6 were 4.2% and 6.4% respectively, and for leptin -
3.3% and 5.4% respectively.
Statistical analysis
Data are expressed as mean ± standard deviation (SD),
median and interquartile range (Q1 to Q3) for variables
that did not follow a normal distribution, or frequencies,
as noted.
To compare the means of continuous variables mea-
sured between sex-specific tertiles of leptin, one way
ANOVA and analysis of covariance with adjustments
(ANCOVA) were used. Categorical data are presented as
percentages and were compared among groups by c2
tests. Correlations between leptin and clinical and labora-
tory parameters were assessed using Spearman rank
order correlation coefficients (because of the skewed dis-
tribution of leptin levels). Multivariate regression analysis
was performed to obtain partial (adjusted) correlations
(R
2). Case-mix-adjusted models were controlled for age,
gender, history of CV disease, presence or absence of dia-
betes mellitus, dialysis vintage and fat mass.
Repeated-measures analysis of variance was performed
by using the MIXED model. Only patients with ≥ 2
study visits were included in the analyses. Base models
were adjusted for age, sex, diabetes status, dialysis vin-
tage, history of cardio-vascular diseases and fat mass. F
Tests were used to assess the significance of the fixed
effects, and P less than 0.05 was considered significant.
To evaluate whether leptin influenced the trends in the
various dependent variables, we included in each base
model terms for individual “leptin-by-time” interactions.
Survival analyses were performed using the Kaplan-
Meier survival curve and the Cox proportional hazard
model. The univariate and multivariate Cox regression
analyses are presented as (HR; CI).
All statistical analyses were performed using SPSS
software, version 16.0 (SPSS Inc, Chicago, IL).
Results
Cross-sectional associations
The 101 prevalent HD patients participating in this
study included 36.6% women; over half of the partici-
pants (51.5%) had diabetes mellitus (DM) and nearly the
same proportion had a history of cardiovascular disease
(46.9%), including myocardial infarction, coronary artery
procedures such as angioplasty or surgery, previous cer-
ebral-vascular accident, or peripheral vascular disease.
Average age was 64.6 ± 11.5 years and median mainte-
nance HD vintage was 31 months (Q1 to Q3, 15.5-51.5
months) at the study initiation. For HD patients at the
start of the cohort, serum leptin averaged (mean ± SD)
37.3 ± 39.4 ng/ml (median, 16.5 ng/ml; Q1 to Q3, 5.60-
71.4 ng/ml).
To examine the relationship between different levels of
serum leptin and relevant demographic, clinical and
laboratory measures, serum leptin levels were divided into
three equal gender specific tertiles (data not shown). Dia-
betes proportion and age distribution were similar across
the three groups. No statistically significant differences
were evident between groups in the use of medications
that may affect inflammatory markers such as statins,
aspirin, or angiotensin-converting enzyme inhibitors (data
not shown). As expected females, tended to have higher
leptin levels than males (p = 0.0001). Body composition
parameters measured by anthropometry and bioelectric
impedance analysis (BIA) including phase angle (PA) were
incrementally greater across increasing leptin tertiles even
after adjustments for baseline demographic and clinical
parameters (age, DM status, dialysis vintage and cardio-
vascular disease in the past). However, these associations
were attenuated after including of fat mass in multivariate
analyses. No significant differences in any of the biochem-
ical markers of nutrition, normalized protein nitrogen
appearance (nPNA), or actual energy or protein intake
normalized to adjusted body weight were found between
the HD patient groups according to leptin tertiles.
At baseline, anthropometric measurements (body mass
index [BMI], triceps skinfold thickness [TSF], mid arm
circumference [MAC] and midarm circumference calcu-
lated [MAMC]) and BIA-derived parameters of body
composition (fat mass index [FMI] and fat free mass
index [FFMI]) correlated positively with serum leptin
levels, in both unadjusted and adjusted (for age, DM sta-
tus, dialysis vintage, and previous cardio-vascular dis-
ease) models. Thus, an increased level of leptin was
associated with better nutritional status (Table 1). Asso-
ciations between levels of serum leptin and the two
laboratory nutritional markers (albumin and cholesterol)
and PA derived by BIA were statistically significant, but
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demographic and clinical parameters including fat mass.
No significant correlations were observed between
serum leptin and nPNA or dietary energy (DEI) and
protein intake (DPI) normalized to adjusted body weight
in both sexes after adjustments for demographic and
clinical parameters including fat mass.
Longitudinal associationas
Linear mixed models were used to study the effects of
longitudinal leptin changes on changes in nutritional
parameters (slopes) over 24 months including fixed
parameters such as age, gender, diabetes status, dialysis
vintage, previous cardio-vascular events, and fat mass
(Table 2). No significant changes in dietary intake or in
any of the biochemical nutritional markers over time
were found. In contrast, a significant reduction in body
composition parameters (both those measured by
anthropometry [BMI, TSF and MAMC] and by BIA
[FMI, FFMI, PA]) over time was observed. However,
leptin did not modulate the changes in outcome
variables over time in our cohort (leptin-by-time inter-
actions were insignificant).
A mixed model including the fixed factors sex, age, DM
status, dialysis vintage, history of CV disease and some of
nutritional parameters predicted variability in leptin levels
during the study presented in Table 3. We observed signif-
icant changes of leptin levels with time (linear estimate ±
SE: -2.5010 ± 0.57 ng/ml/2y; p < 0.001). The effect of long-
itudinal changes of FMI on serum leptin variability over
time was evident according to this model.
Of interest, a significant reduction over time was asso-
ciated with a more rapid decline in leptin levels in the
highest leptin tertile in both unadjusted (p = 0.007 for
leptin-by-time interaction) and fully adjusted (p = 0.047
for leptin-by-time interaction) models (Figure 2).
Survival analysis
During an average follow-up of 35 months (median, 40
months; Q1 to Q3, 17-52), 33 patients died: 11 (32%) in
the low tertile group, 12 (35%) in the median tertile
group and 10 (30%) in the high tertile group, with a med-
ian time to death of 25 months (Q1 to Q3, 14-40
months). Cumulative incidences of survival were unaf-
fected by the baseline serum leptin levels (Figure 3). To
further assess the possible association of baseline serum
leptin level with cardio-vascular morbidity and mortality,
cumulative hazards of all-cause death and first composite
cardio-vascular event from Cox regression (after adjust-
ment for baseline demographic parameters and fat mass)
were calculated. First cardio-vascular event was defined
as myocardial infarction (MI), requiring coronary artery
procedures such as angioplasty or surgery, cerebral-vas-
cular accident (CVA), or peripheral vascular disease
(PVD), requiring angioplasty, bypass or amputation and
diagnosed after the participant entered the study. No sta-
tistically significant differences in hazards between the
different groups according leptin tertiles were observed.
Additionally, no differences were found by Cox regres-
sion analysis in terms of survival probabilities from the
analysis of all-cause mortality for each 10 ng/ml increase
in baseline serum leptin (data not shown).
Thus, although chronic HD patients with higher base-
line leptin had better nutriti o n a ls t a t u sa se v i d e n c e db y
their significantly more favorable body composition
parameters at the start of the study, this disparity did
not appear to widen over the 24 months of follow-up;
thus, leptin levels did not predict body composition
parameter changes over time. Moreover, no survival
advantage of the high leptin group was found in our
observational cohort.
Discussion
In the present study, we wished to determine whether
changes of serum leptin levels are correlated with
Table 1 Unadjusted and multivariate adjusted
Spearman’s correlation coefficients of baseline serum
leptin and nutritional clinical and laboratory parameters
in the study population at baseline
Raw Adjusted
a
RPRP
Dietary intake
Energy intake (kcal/kg/d) -0.133 0.21 -0.170 0.17
Protein intake (g/kg/d) -0.231 0.027 -0.177 0.15
nPNA 0.005 0.97 0.079 0.46
Biochemical markers
Albumin (g/dL) 0.216 0.030 0.065 0.55
Creatinine (mg/dL) -0.014 0.89 0.082 0.44
Cholesterol (mg/dL) 0.217 0.029 0.060 0.57
Transferrin (mg/dL) 0.161 0.11 0.056 0.61
IL-6 (mcg/ml) -0.105 0.31 0.012 0.92
Anthropometric measurements
BMI (kg/m
2) 0.758 < 0.001 - -
TSF (mm) 0.696 < 0.001 0.319 0.008
MAC (cm) 0.751 < 0.001 0.491 < 0.001
MAMC (cm) 0.486 < 0.001 0.378 0.001
Bioimpedance analysis
FMI (kg/m
2) 0.862 < 0.001 --
FFMI (kg/m
2) 0.247 0.013 0.296 0.014
Phase angle (°) 0.273 0.006 0.128 0.297
Correlation coefficient values ≥ 0.25 appear in bold.
a All case-mix-adjusted models include age, gender, DM status, dialysis
vintage, CV disease in the past and fat mass.
Abbreviations: nPNA, normalized protein nitrogen appearance; IL-6, interleukin-
6; BMI, body mass index; TSF, triceps skinfold thickness; MAC, mid-arm
circumference; MAMC, mid-arm muscle circumference calculated; FMI, fat mass
index; FFMI, fat-free mass index, DM, diabetes mellitus; CV, cardio-vascular.
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based on mixed-effects model with linear trends for variable and fixed parameters
95% confidence interval
Estimate Lower Upper F P
DEI (kcal/kg/d) -0.0154 -0.3756 0.3448 0.007 0.93
Albumin (g/L) 0.0369 -0.7011 0.7750 0.010 0.92
IL-6 (mcg/ml) 0.0534 -0.0397 0.1465 1.289 0.26
EPO dose (x10
2u/kg/w) -0.0001 -0.0176 0.0173 0.0001 0.99
FMI (kg/m
2) 5.4558 4.4808 6.4308 121.918 < 0.001
Age (years) -0.2072 -0.5850 0.1706 1.187 0.28
Gender (men v women) -11.7523 -21.2601 -2.2445 6.018 0.016
DM (yes v no) -0.7272 -9.2410 7.7867 0.029 0.87
History of CV disease (yes v no) -0.9497 -9.6537 7.7544 0.047 0.83
Dialysis vintage (months) 0.0341 -0.0849 0.1531 0.325 0.57
Time (months) -2.5010 -3.5814 -1.4205 21.650 < 0.001
NOTE: The Table represents a simple Mixed-Model with leptin as dependent variable, and presented nutritional parameters and fixed factors (age, gender, DM
status, dialysis vintage and history of CV disease) as independent variables. The model takes into account every measurements of leptin and presented
nutritional variables in each time point for each patient separately.
Abbreviations: DEI, daily energy intake; IL-6, interleukin-6; EPO, erythropoietin; FMI, fat mass index; DM, diabetes mellitus; CV, cardio-vascular.
Table 2 Regression coefficients with 95% Confidence Intervals for the effect of longitudinal leptin changes on
nutritional parameters changes (slopes) during 24 months based on mixed-effects model with linear trends for
variable and fixed parameters
95% confidence interval
Estimate Lower Upper F P P
a
Dietary intake
Δ DEI (kcal/kg/d) -0.2285 -0.7376 0.2699 0.914 0.32 0.46
Δ DPI (g/kg/d) -0.0119 -0.0334 0.0134 1.087 0.30 0.86
Δ nPNA 0.0020 -0.1572 0.0197 0.049 0.83 0.47
Biochemical markers
Δ Albumin (g/L) -0.2665 -0.4403 0.0928 2.371 0.13 0.37
Δ Transferrin (mg/dL) -1.6025 -3.4108 0.2059 3.111 0.08 0.81
Δ Creatinine (mg/dL) -0.0261 -0.1158 0.0635 0.336 0.56 0.52
Δ Cholesterol (mg/dL) -2.9192 -4.8957 0.9428 1.676 0.24 0.32
Δ IL-6 (mcg/ml) 2.8850 -1.8151 3.9548 0.971 0.34 0.46
EPO dose(x10
2u/kg/w) 5.9104 -1.6371 13.4579 2.429 0.12 0.90
Anthropometric measurements
Δ BMI (kg/m
2)
b -0.1259 -0.2389 -0.0129 5.011 0.030 0.57
Δ TSF (mm) -0.4376 -0.7181 -0.1571 10.100 0.003 0.09
ΔMAC (cm) 0.0409 -0.0945 0.1764 0.374 0.55 0.26
ΔMAMC (cm) -0.2066 -0.3356 -0.0777 10.550 0.002 0.20
Bioimpedance analysis
Δ FMI (kg/m
2)
b -0.1467 -0.2697 -0.0211 5.512 0.021 0.76
Δ FFMI (kg/m
2) -0.1459 -0.2044 -0.0874 24.760 < 0.001 0.15
Δ Phase angle (°) -0.1018 -0.1377 -0.0659 31.898 < 0.001 0.38
NOTE: All nutritional variables presented in Table were modeled separately as dependent variables, whereas independent variables included fixed factors (such as
age, gender, diabetes status, dialysis vintage, past cardio-vascular disease and fat mass) and leptin as continuous variable. Terms for individual “leptin-by-time”
interactions were included in each model. The model takes into account every measurements of leptin and presented nutritional variables in each time point for
each patient separately. Presented regression coefficients demonstrate changes in outcome variables with time (24 months).
a P for trend for leptin-by-time interactions.
b FMI and BMI were adjusted only by age, gender, DM status, history of cardio-vascular disease and dialysis vintage.
Abbreviations: DEI, daily energy intake; DPI, daily protein intake; nPNA, normalized protein nitrogen appearance; IL-6, interleukin-6; EPO, erythropoietin; BMI, body
mass index; TSF, triceps skinfold thickness; MAC, mid-arm circumference; MAMC, mid-arm muscle circumference calculated; FMI, fat mass index; FFMI, fat-free
mass index; DM, diabetes mellitus; CV, cardio-vascular.
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hemodialysis patients. We observed that despite the
strong and significant cross-sectional associations
between serum leptin and body composition parameters
at baseline, leptin levels did not reflect changes in nutri-
tional status in our population.
Our study confirms several previous cross-sectional
studies in which elevated serum leptin levels were
demonstrated to be positively associated with several
nutritional markers (laboratory or body composition
parameters, mainly BMI and fat mass) in chronic HD
patients [14,20,21,23-25]. HD patients treated with
megestrole acetate (24), growth hormone [31] or high-
calorie supplementation [32] demonstrated progressively
increased serum leptin parallel to an improved nutri-
tional state.
However, not all studies are consistent with positive
associations between elevated levels of leptin and several
nutritional parameters in ESRD patients. An inverse cor-
relation was observed between leptin/fat mass and dietary
intake, as well as with significantly lower lean tissue mass
in chronic renal failure (23 patients) and ESRD patients
receiving PD (24 patients) and HD (22 patients) therapy
in study by Young et al [5]. In a cross-sectional study of
28 dialysis patients and 41 healthy control subjects,
Johansen et al [20] showed that leptin levels were nega-
tively correlated with albumin and PCR, suggesting a
possible negative role of leptin in nutrition. Based on
longitudinal observation, Stenvinkel et al [18] demon-
strated that increases in serum leptin levels of 36 perito-
neal dialysis patients were associated with a decrease in
lean body mass. The discrepancies between these studies
may be related to the population recruited, to their small
sample size, and to their design; specifically, serum leptin
levels were measured among patients with varying
degrees of CRF, some of whom were undergoing mainte-
nance hemodialysis and peritoneal dialysis, and in healthy
controls [5,18,20]; many of these studies had a low
Figure 3 Kaplan-Meier curves of surviving patients comparing
subgroups of patients stratified by baseline serum leptin
tertiles.
Figure 2 Leptin levels decline over time in the study population. Changes in estimated marginal means of serum leptin levels at baseline
(month 0), month 6, month 12, month 18 and month 24 in the study population groups according to sex-specific tertiles* of baseline serum
leptin: 1. Unadjusted model: P = 0.007 for leptin-by-time interaction; 2. Fully adjusted model (for age, gender, DM status, dialysis vintage,
previous cardio-vascular morbidity and fat mass): P = 0.047 for leptin-by-time interaction. *Median (interquartile range) leptin (ng/ml) tertiles for
men (n = 64) were 1.70 (1.2-2.4), 10.2 (7.6-13.8) and 38.3 (26.2-81.3) and for women (n = 37) were 15.8 (9.3-18.3), 68.0 (41.4-85.9) and 112.6 (109.2-
116.0).
Beberashvili et al. Nutrition Journal 2011, 10:68
http://www.nutritionj.com/content/10/1/68
Page 7 of 10number of study participants [5,18,20,23-25] and a
majority of these studies were cross-sectional
[5,20,23,25].
Leptin, a regulator of eating behavior, has been shown
to be a major determinant of anorexia in uremic animals
via signaling through the hypothalamic melanocortin sys-
tem [15]. Subsequently, a recent experimental study by
Cheung et al [33] showed that intraperitoneal administra-
tion of the melanocortin-4 receptor (MC4-R) antagonist
NBI-12i stimulates food intake and weight gain in uremic
mice. However, the effects of leptin in uremic patients
are not unequivocal. Relevant to our findings, Bossola at
al [17] demonstrated that serum leptin levels were not
different in anorexic and in non-anorexic hemodialysis
patients. Several other studies failed as well to demon-
strate any role of hyperleptinemia on reduced dietary
intake in ESRD patients receiving maintenance HD treat-
ment [5,16,34]. Since hyperleptinemia is common in HD
patients mainly due to impaired renal clearance [20], it
seemed reasonable to assume that selective leptin resis-
tance (such as occurs in obese humans [35]) is the
responsible mechanism for attenuation of the negative
effect of leptin on appetite, and accordingly, on dietary
intake under conditions of continuous stimulation. The
molecular mechanisms of leptin resistance, with a focus
on the contribution of the intracellular tyrosine residues
in the hypothalamic receptor of leptin (LEPRb) and their
interaction with the negative feedback regulators, sup-
pressor of cytokine signaling 1 and 3 (SOCS1 and
SOCS3), are described in a recent study by Knobelspies
et al [36].
Thus, although the cross-group comparisons confirm
that hyperleptinemia is associated with better body com-
position parameters, no unequivocal associations in
terms of biochemical data or dietary intake with serum
leptin levels are evident in HD patients according to the
available literature. Our study confirms these data.
Another finding of the present study was that 24
months of HD was associated with a significant reduc-
tion of plasma leptin levels, with a more rapid decline
observed in patients with higher baseline leptin levels.
Only limited information is available on the relationship
between longitudinal serum leptin measurements and
nutritional characteristics in chronic HD patients
[18,32]. To the best of our knowledge, the present study
is the first long-term longitudinal study to show the
relationship between serum leptin level and nutritional
status in ESRD patients receiving maintenance HD ther-
apy. Several mechanisms may be involved in decrease of
serum leptin levels over time in hemodialysis patients.
These include, the increasing use of high flux and
super-flux hemodialyzers [37], and/or use of alternative
dialysis strategies such as hemodiafiltration [38]; recom-
binant human erythropoietin treatment (generally
followed by a significant decline of leptinaemia in hemo-
dialysed patients [39]); chronic inflammation (under the
assumption that leptin, like albumin or transferrin, is a
negative acute phase protein in chronic HD patients
[22], although other studies [40] do not support this
mechanism); metabolic acidosis, which can reduce the
release of leptin from adipose tissue [41]; and finally, a
decrease in fat mass leading to a decrease in the rate of
leptin biosynthesis [14,18] (based on an insulin or a
nutrient-sensing pathway regulating leptin gene expres-
sion in fat tissue [42]). Although patients in our facility
were all treated using low flux hemodialysis, reduction
of BMI and accordingly of fat mass over 24 months of
the study may explain this longitudinal decrease of
serum leptin levels in our cohort.
Of interest is the observation that adverse changes in
body composition parameters occur over time, supporting
the hypothesis that end-stage renal disease is associated
with wasting as proposed in some [43,44] but not all [45]
of the previous studies. The results of our study were con-
sistent with those reported by Johansen et al [43] who did
not find significant changes in any of the biochemical mar-
kers with time, but a significant reduction in phase angle
over 1 year follow up was evident in prevalent HD
patients. In parallel, together with reduced body composi-
tion parameters over time, we observed a longitudinal
decline in serum leptin levels in our cohort. However, the
lack of an association between serum leptin levels and
future changes in body composition parameters (as exhib-
ited by non-significant leptin-by-time interactions), sug-
gests that the levels of leptin follow body composition
(mainly fat mass) trajectory or its accompanying metabolic
changes, rather than governing it.
Finally, serum leptin level did not appear as a useful pre-
dictor of all cause mortality or cardio-vascular morbidity
in our study population during up to 4 years of observa-
tion. In this aspect, our findings support the results of ear-
lier study by Tsai et al [46]. Although Scholze et al [26]
showed a paradoxical reverse association between leptin
level and clinical outcome in 71 chronic HD patients, our
patients did not show such an association. The difference
between our results and theirs might have been caused by
differences in the cohorts. First, the population presented
by Scholze et al [26] had a lower BMI at baseline than our
patients, and no body composition parameters were mea-
sured. Further, the prevalence of diabetes mellitus was
much greater in patients in the lower leptin group than in
patients of the higher leptin group in the cohort of Scholze
et al [26]. Indeed, HD patients with diabetes have a
poor prognosis [4] that might be the cause of the lower
survival rate in the lower leptin group in the above study
[26]. While low levels of leptin may reflect a state of mal-
nutrition in HD patients, proatherogenic effects of hyper-
leptinemia were linked to an adverse cardiovascular profile
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of long-term benefits of hyperleptinemia in terms of survi-
val of chronic HD patients could reflect the modulating
influence of proatherogenic effects of high serum leptin
levels. Finally, no relationships between serum leptin levels
and previous cardio-vascular events were found by Diez et
al [47] in a retrospective study on 82 dialysis patients. Zoc-
cali et al [40] also did not show any difference in cardio-
vascular event-free survival in cohort of 192 hemodialysis
patients after their stratification on the basis of the median
value of plasma leptin.
Some limitations of the present study should be con-
sidered. First, this study is based on a relatively small
sample size limiting detection of more subtle changes
over time. Second, this study used only an observational
approach, without manipulation of exposure factors, and
therefore, no definitive cause-and-effect relationship can
be derived for any of the risk factors analyzed. Dietary
intake assessed by 3 day food records is another limita-
t i o no ft h es t u d y ,a sr e s u l t sc a nb es u b j e c t i v ea n d
incomplete, and can vary considerably from day to day
as a result of dialysis treatment sessions and associated
disturbances in food intake. Finally, significant circadian
fluctuations of plasma leptin (regardless of the underly-
ing degree of glucose tolerance, fasting, or diet) can cer-
tainly obscure some small but significant changes in
plasma leptin [48] and may be a source of potential bias
for longitudinal observation. Nevertheless, the present
study has the advantage of providing long-term longitu-
dinal data on the relationship between serum concentra-
tions of leptin and nutritional parameters in prevalent
HD patients.
Conclusions
In conclusion, we found positive linear associations
between serum leptin levels and body composition,
whereas no significant relations in terms of biochem-
ical data or dietary intake were evident in our cohort
at baseline. Analyzing longitudinal data we concluded
that any influence of serum leptin levels on nutritional
status is limited to mirroring attained BMI and fat
mass trajectory. Further, nutritional advantage at base-
line of the study population with hyperleptinemia did
not translate into long-term benefits in terms of survi-
val. Taken together, our results suggest that in our
cohort, leptin levels reflect fat mass depots, rather than
independently contributing to uremic anorexia or
modifying nutritional status and/or survival in chronic
HD patients. These results are of particular importance
if the use of subcutaneous injections of recombinant
methionyl leptin [49] or leptin removal by super-flux
polysulfone dialysers [37] is contemplated as a thera-
peutic intervention.
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